文献速递慢性肾脏病肾移植遗传性与小管间质肾病

多学科框架将肾脏病临床基因检测中的意义未明变异转化为明确分类

Framework From a Multidisciplinary Approach for Transitioning Variants of Unknown Significance From Clinical Genetic Testing in Kidney Disease to a Definitive Classification.
PubMed 文献 · Kidney Int Rep · 2022-07-07

本文介绍一个由临床医生、分子生物学家和诊断遗传学家组成的多学科团队设计的框架,用于评估肾脏病临床基因检测中意义未明变异(VUS)的致病性。该框架应用健康系统队列进行深度表型分析、检查现有遗传数据库并进行功能测试,成功为肾移植候选者返回的HNF1B-p.Arg303His VUS提供了致病性证据。该变异与已知HNF1B致病变异相比肾脏表现负担相似,且高于非携带者。

要点

  • 多学科框架可评估肾脏病基因检测中VUS的致病性。
  • HNF1B-p.Arg303His被证实与已知致病变异肾脏表现负担相似。
  • 该框架对活体肾捐赠安全评估和临床生物标志物检测有重要意义。

核心结论

  • 多学科框架可为肾脏病临床基因检测中的VUS提供致病性证据并实现分子诊断。
  • 该框架对HNF1B相关表现(肾脏病、糖尿病、低镁血症)的监测管理和活体肾捐赠安全有重要意义。
  • 该工作模型可能适用于其他遗传病因疾病。

研究设计与样本

  • 由临床医生、分子生物学家和诊断遗传学家组成的多学科团队设计蓝图。
  • 蓝图包括使用健康系统队列进行深度表型分析、检查现有遗传数据库和功能测试。

主要发现

  • HNF1B-p.Arg303His变异携带者的肾脏表现负担与已知HNF1B致病变异携带者相似。
  • 该变异携带者的肾脏表现负担高于非携带者。
  • 该框架为HNF1B-p.Arg303His提供了致病性证据。

临床怎么用

  • 分子诊断有助于对HNF1B相关表现进行监测和管理,并对活体肾捐赠安全有重要影响。
  • 候选基因-变异对可用于检测相关通路异常的临床生物标志物。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Monogenic causes in over 300 kidney-associated genes account for approximately 12% of end stage kidney disease (ESKD) cases. Advances in sequencing and large customized panels enable the noninvasive diagnosis of monogenic kidney disease at relatively low cost, thereby allowing for more precise management for patients and their families. A major challenge is interpreting rare variants, many of which are classified as variants of unknown significance (VUS). We present a framework in which we thoroughly evaluated and provided evidence of pathogenicity for HNF1B-p.Arg303His, a VUS returned from clinical diagnostic testing for a kidney transplant candidate. METHODS: A blueprint was designed by a multidisciplinary team of clinicians, molecular biologists, and diagnostic geneticists. The blueprint included using a health system-based cohort with genetic and clinical information to perform deep phenotyping of VUS heterozygotes to identify the candidate VUS and rule out other VUS, examination of existing genetic databases, as well as functional testing. RESULTS: Our approach demonstrated evidence for pathogenicity for HNF1B-p.Arg303His by showing similar burden of kidney manifestations in this variant to known HNF1B pathogenic variants, and greater burden compared to noncarriers. CONCLUSION: Determination of a molecular diagnosis for the example family allows for proper surveillance and management of HNF1B-related manifestations such as kidney disease, diabetes, and hypomagnesemia with important implications for safe living-related kidney donation. The candidate gene-variant pair also allows for clinical biomarker testing for aberrations of linked pathways. This working model may be applicable to other diseases of genetic etiology.

来源:Kidney Int Rep,查看原文。版权归原作者所有。

引用

  1. Mirshahi UL, Bhan A, Tholen LE, et al. Framework From a Multidisciplinary Approach for Transitioning Variants of Unknown Significance From Clinical Genetic Testing in Kidney Disease to a Definitive Classification. Kidney Int Rep. 2022. PMID: 36090499. doi:10.1016/j.ekir.2022.06.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。